1. Chen ML et al. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report. Eur J Pharm Sci. 2010;40(2):148–53.
2. Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms. [Online].; 1997 [cited 2016 06 16. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070640.pdf .
3. Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drug s Submitted Under an ANDA. Recommended by U.S. Food and Drug Administration in December 2013. [Online]. [cited 2016 06 16. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdf .
4. Davit BM and Conner DP. Bioequivalence Testing for Modified-Release Dosage Forms. In Amidon G, Lesko L, Shah V, Hilfinger J, editors. International Bioequivalence Standards: A New Era.: TSRL Inc.; 2006. p. 271.
5. Qiu Y, Zhou D. Understanding design and development of modified release solid oral dosage forms. J Valid Technol. 2011;17(2):23–32.